Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

Inclusion Criteria: * Confirmed diagnosis of: * Advanced solid tumor that is no longer responding to therapies OR * Advanced or metastatic NSCLC that has previously been treated with erlotinib or gefitinib * ECOG Performance Status 0-1 * Adequate organ and bone arrow function as defined by hematological and serum chemistry limits * At least 18 years old * Both men and women must practice adequate contraception * Informed consent Exclusion Criteria: * Restriction of some therapies/medications within specific timeframes prior to enrollment and during the study including prior therapy with PI3K, cytotoxic chemotherapy, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase inhibitors, non-cytotoxic hormonal agents * Erlotinib intolerant * Taking oral corticosteroids chronically or \> 1 mg/day warfarin * Not recovered from the toxic effects of prior therapy * History of diabetes mellitus and an HgbA1c \> 7% * Uncontrolled intercurrent illness * Pregnant or breastfeeding * Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study. * HIV positive * Diagnosis of another malignancy may exclude subject from study